Inflammation, Skin Patents (Class 514/886)

Cross-Reference Art Collections

Topical treatment (Class 514/887)
  • Patent number: 6149896
    Abstract: Cosmetic and cosmeceutical compositions which enhance repair of damage caused to human DNA caused by excessive exposure to sunlight or to other radiation causing such damage. The active ingredients are a synergistic combination of nor-dihydroguiaretic acid (NDGA) and niacinamide. Optional components are propyl gallate or other antioxidants. Composition may further contain sun-screen additives.
    Type: Grant
    Filed: February 5, 1999
    Date of Patent: November 21, 2000
    Inventors: Emanuel Riklis, deceased, by Ruth Riklis, legal representative, by Eran Riklis, legal representative, by Liatt Oren-Riklis, legal representative, by Eitan Riklis, legal representative
  • Patent number: 6136800
    Abstract: This invention describes the new 17-difluoromethylene-estratrienes of general formula I ##STR1## in which R.sup.1 is a hydrogen atom or a C.sub.1 -C.sub.10 alkyl group,R.sup.5 is a methyl or ethyl group, andR.sup.2 is a hydrogen atom or a C.sub.1 -C.sub.10 alkyl group in .alpha.- or .beta.-position,R.sup.3 is a hydrogen atom or a C.sub.1 -C.sub.10 alkyloxy group in .alpha.- or .beta.-position,R.sup.4 is a hydrogen atom in .alpha.- or .beta.-position, and A, B, D, E and G each is a hydrogen atom, and optionally at least one of substituent pairsG and R.sup.2, R.sup.2 and R.sup.4, R.sup.4 and A, A and R.sup.3, B and D, D and E is a double bond.
    Type: Grant
    Filed: March 8, 1999
    Date of Patent: October 24, 2000
    Assignee: Schering Aktiengesellschaft
    Inventors: Rolf Bohlmann, Gabor Rubayi
  • Patent number: 6132762
    Abstract: A transcutaneous therapeutic formulation comprising marijuana and a carrier for the treatment of pain, inflammation, arthritis and related disorders in humans and animals.
    Type: Grant
    Filed: May 5, 1998
    Date of Patent: October 17, 2000
    Inventor: Walter Cristobal
  • Patent number: 6124284
    Abstract: Novel compounds of formula (1) together with their salts and solvates have a number of uses in medicine, in particular as central muscle relaxants.
    Type: Grant
    Filed: July 16, 1998
    Date of Patent: September 26, 2000
    Assignee: Glaxo Wellcome Inc.
    Inventors: James Leroy Kelley, Gregory Cooksey Rigdon, Barrett Randolph Cooper, Ed Williams McLean, David Lee Musso, Gloria Faye Orr, Jeffrey Leaman Selph, Virgil Lee Styles
  • Patent number: 6124266
    Abstract: The invention refers to the use of a sulpholipid SQDG having formula (I), wherein R.sub.1 and R.sub.2, which are the same or different, are hydrogen or saturated or unsaturated, optionally hydroxy-substituted acyl groups, protonated or as a salt, for the preparation of a pharmaceutical composition for the treatment of inflammatory skin diseases or disorders, especially psoriasis. A pharmaceutical composition comprising an SQDG compound in combination with a polyunsaturated fatty acid and a therapeutically acceptable carrier is also described.
    Type: Grant
    Filed: April 27, 1999
    Date of Patent: September 26, 2000
    Assignee: Scotia Lipid Teknik AB
    Inventors: Mervi Vasange, Wenche Rolfsen, Lars Bohlin
  • Patent number: 6121329
    Abstract: An external preparation for topical administration which aims at inhibiting rejection reactions at organ or bone marrow transplantation or treating autoimmune diseases or allergic diseases and contains as the active ingredient 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof.
    Type: Grant
    Filed: August 27, 1997
    Date of Patent: September 19, 2000
    Assignee: Yoshitomi Pharmaceutical Industries, Ltd.
    Inventors: Tsuneo Fujii, Tadashi Mishina, Koji Teshima, Tomonori Imayoshi
  • Patent number: 6114572
    Abstract: The present invention provides compounds of the formula ##STR1## wherein X is selected from the group consisting of ##STR2## Y is thio, oxy or a methylene group; Z is hydrogen or --C(O)--(CH.sub.2).sub.m --Q wherein Q is hydrogen or --COOH and m is an integer 1, 2, 3 or 4;R.sub.1 is C.sub.1 -C.sub.6 alkyl; andR.sub.2, R.sub.3 and R.sub.4 are each independently hydrogen or C.sub.1 -C.sub.6 alkyl;or a stereoisomer thereof; useful for the treatment of atherosclerosis and chronic inflammatory disorders; for inhibiting cytokine-induced expression of VCAM-1 and/or ICAM-1; for inhibiting the peroxidation of LDL lipid; for lowering plasma cholesterol; and as anti-oxidant chemical additives useful for preventing oxidative deterioration in organic materials.
    Type: Grant
    Filed: November 19, 1997
    Date of Patent: September 5, 2000
    Assignee: Hoechst Marion Roussel, Inc.
    Inventors: Roger A. Parker, Paul S. Wright, Steven J. Busch, Kim S. Chen, Mark T. Yates
  • Patent number: 6113929
    Abstract: Plant resin exuded by poison ivy, poison oak, poison sumac and other plant resins are removed from the skin by successive applications of an alkaline cleanser and acidic stripper. The skin is first thoroughly washed with the alkaline cleanser. After rinsing the cleanser from the skin, the skin is daubed with the acidic stripper. The alkaline cleanser is a mixture of water, soap, turpentine, a mild abrasive, and mineral spirits. The acidic stripper is a mixture of an acid, and astringents such as tannin and witch hazel extract.
    Type: Grant
    Filed: August 3, 1998
    Date of Patent: September 5, 2000
    Inventor: A. Robert Karl
  • Patent number: 6106846
    Abstract: The present invention relates to the use of at least one thermal spring water from the Vichy basin as substance P antagonist in a cosmetic composition or for the preparation of a pharmaceutical composition. The invention also relates to the use of at least one thermal spring water from the Vichy basin in a cosmetic composition or for the preparation of a pharmaceutical composition, more especially a dermatological composition, intended for treating disorders associated with excessive synthesis and/or release of substance P.
    Type: Grant
    Filed: September 19, 1996
    Date of Patent: August 22, 2000
    Assignee: Societe L'Oreal S.A.
    Inventors: Lionel Breton, Jacques Leclaire, Olivier de Lacharriere
  • Patent number: 6106848
    Abstract: Stable, topically applicable oil-in-water bioaffecting emulsions having intermediate viscosity, characteristically ranging from 3 to 10 Pa.multidot.s, comprise (a) from 30% to 50% by weight of at least one pro-penetrating glycol, (b) at least one emulsifying agent, advantageously an anionic amphiphilic polymer, and (c) at least one biologically active agent, for example an active agent that modulates skin differentiation and/or proliferation and/or pigmentation, an anti-inflammatory, an antibacterial, an antifungal, etc.
    Type: Grant
    Filed: September 22, 1997
    Date of Patent: August 22, 2000
    Assignee: Centre International de Recherches Dermatologiques
    Inventors: Isabelle Preuilh, Nathalie Willcox
  • Patent number: 6103737
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I: ##STR1## and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.
    Type: Grant
    Filed: July 2, 1998
    Date of Patent: August 15, 2000
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Anthony J. Cocuzza, Frank W. Hobbs, James P. Beck, Paul J. Gilligan
  • Patent number: 6100235
    Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, and methods of treatment using the IL-17 receptors are disclosed. The isolated receptors can be used to regulate an immune response.
    Type: Grant
    Filed: February 11, 1998
    Date of Patent: August 8, 2000
    Assignee: Immunex Corporation
    Inventors: Zhengbin Yao, Melanie K. Spriggs, William C. Fanslow
  • Patent number: 6080782
    Abstract: Compounds of formula I are selective cyclic nucleotide phosphodiesterase (PDE) inhibitors (namely of type IV). They and pharmaceutical compositions in which they are active ingredients are useful as bronchial therapeutics, for elimination of erectile dysfunction and for treatment of disorders, particularly those of inflammatory nature. The compounds are distinguished by low toxicity, good enteral absorption (high bioavailability), a great therapeutic breadth and the absence of significant side effects.
    Type: Grant
    Filed: November 18, 1997
    Date of Patent: June 27, 2000
    Assignee: BYK Gulden Lomberg Chemische Fabrik GmbH
    Inventors: Wolf-Rudiger Ulrich, Thomas Martin
  • Patent number: 6068845
    Abstract: This invention provides a pharmaceutical preparation or cosmetic, and a method for effectively inhibiting the abnormal accumulation of extra-cellular matrices. In addition, a method for preventing or treating a disease resulting from the abnormal accumulation of extra-cellular matrices is also disclosed. The pharmaceutical preparation or cosmetic contains as an effective ingredient at least one substance selected from the group consisting of the extract of a plant belonging to the genus Artemisia, the genus Forsythia, the genus Sophorak the genus Pheutn the genus GI rhiza, the genus Arctium, the genus Anemarrhena, the genus Aralia, the genus Anelicia, the genus Akebia or the genus Atractylodes, the genus Akebia or the genus Atractilodes, malotilate, 2,2'-dipyridyl and o-phenanthroline.
    Type: Grant
    Filed: June 17, 1997
    Date of Patent: May 30, 2000
    Assignee: Institute for Advanced Skin Research Inc.
    Inventors: Hiroe Aoki, Eijiro Hara, Tetsuji Hirao
  • Patent number: 6069128
    Abstract: The present invention relates to membrane-permeable peptides which are intracellular agonists and/or antagonists of chemotactic factor receptors rendered hydrophobic through acylation and acetoxymethylation of their amine and acid functional groups. The modified peptides of the present invention are loaded into cells. The acetoxymethyl esters are cleaved by non-specific esterases rendering the peptides active in the intracellular compartments of the cells. The effects of the introduction of transformed specific peptides corresponding to intracellular regions common to the major chemokine receptors are illustrated. These peptides completely inhibited chemotactic factor and chemokine-induced calcium mobilization. Furthermore, leukocytes of mice intravenously injected with these peptides failed to migrate towards chemokines(IL-8).
    Type: Grant
    Filed: July 13, 1998
    Date of Patent: May 30, 2000
    Assignee: Universite Laval
    Inventors: Paul H. Naccache, Bassam B. Damaj, Shaun R. McColl
  • Patent number: 6063406
    Abstract: The present invention includes a process and composition for treating skin disorders. The composition of the present invention comprises 94.0 to 99.2 percent by weight of cation-free water, 0.1 to 1.0 percent by weight of Calcium chloride, 0.0 to 2.0 percent by weight of linear long chain polyphosphate, 0.1 to 1.0 percent by weight of sodium bicarbonate and 0.5 to 3.0 percent by weight of cross-linked polyacrylamide polymer.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: May 16, 2000
    Assignee: Chemcraft, Inc.
    Inventor: Richard S. Hornack
  • Patent number: 6060449
    Abstract: There is provided an inhibitor of angiogenesis induced by growth of the vascular endothelial cells that comprises Tissue Factor Pathway Inhibitor (TFPI) as an active ingredient. The TFPI-containing preparation of the present invention can effectively inhibit angiogenesis induced by growth of the vascular endothelial cells, and thus, is quite efficacious for preventing and treating the conditions of diseases associated with angiogenesis such as malignant tumors.
    Type: Grant
    Filed: September 10, 1998
    Date of Patent: May 9, 2000
    Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
    Inventors: Tsutomu Hamuro, Yo Nakahara, Sumiyo Takemoto, Seiji Miyamoto
  • Patent number: 6051244
    Abstract: Topical application of fructose-1,6-diphosphate, its derivatives and/or precursors are used for treating or preventing epidermal or mucosal aging and inflammation. In preferred embodiments, the fructose diphosphate (or its derivative) is applied in admixture with a dermally, ophthalmically, orally, or nasally acceptable carrier. Topical application lessens symptoms of urticaria, atopic dermatitis and allergic rhinitis and conjunctivitis among other inflammatory conditions and inhibit microscarring of the dermis.
    Type: Grant
    Filed: August 14, 1998
    Date of Patent: April 18, 2000
    Inventor: Nicholas V. Perricone
  • Patent number: 6045788
    Abstract: A method of activating the immune system of a subject comprises the chronic administration of low doses of an agent such as IL-2, fusion proteins thereof and derivatives thereof that are pharmaceutically acceptable. The agent is provided as a dermal composition, transdermal delivery device and electrotransport device as well as in the form of a kit for self-administration.
    Type: Grant
    Filed: February 28, 1996
    Date of Patent: April 4, 2000
    Assignee: Cornell Research Foundation, Inc.
    Inventor: Kendall A. Smith
  • Patent number: 6039955
    Abstract: A nontoxic, therapeutic agent having pharmacological activity comprising concentrated extract of Larrea tridentata plant material and ascorbic acid, an ascorbic acid ester, an ascorbic acid salt, butylated hydroxyanisole, butylated hydroxytoluene, hydrogen sulfide, hypophosphorous acid, monothioglycerol, potassium bisulfite, propyl gallate, sodium bisulfite, sodium hydrosulfite, sodium thiosulfate, sulfur dioxide, sulfurous acid, a tocopherol or vitamin E is made by a process in which the plant material is extracted using an organic solvent, preferably acetone, and is then saturated with one of the listed reducing agents acid to reduce the toxic NDGA quinone, which naturally occurs in the plant material, to NDGA itself.
    Type: Grant
    Filed: June 10, 1999
    Date of Patent: March 21, 2000
    Assignee: Larreacorp, Ltd.
    Inventors: Robert A. Sinnott, W. Dennis Clark, Kenneth Frank DeBoer
  • Patent number: 6039949
    Abstract: The present invention is directed to a method of preparation and the composition of a water soluble extract of the plant species Uncaria. The present invention is also directed to the pharmaceutical use of the composition for the enhancement of the immune, anti-inflammatory, anti-tumor and DNA repair processes of warm blooded animals. The present preparation of the water soluble extract of the plant species Uncaria results in the depletion of many of the ingredients which lead to various toxic side effects associated with other extracts or compositions derived from Uncaria. Also, the present preparation leads to the depletion of many of the active ingredients commonly associated with other extracts and compositions of the plant species Uncaria.
    Type: Grant
    Filed: February 27, 1997
    Date of Patent: March 21, 2000
    Assignee: CampaMed, Inc.
    Inventor: Ronald W. Pero
  • Patent number: 6030643
    Abstract: Pharmaceutical compositions containing potassium, sodium or Tris salt of oxaprozin as an active agent. The pharmaceutical compositions of the present invention are useful in eliminating or ameliorating pain and in the treatment of inflammation and inflammation associated disorders such as rheumatoid arthritis and osteoarthritis.
    Type: Grant
    Filed: May 16, 1997
    Date of Patent: February 29, 2000
    Assignee: G.D. Searle & Co.
    Inventors: Mark E. Adams, Subhash Desai, Aziz Karim, Kalidas Paul, Douglas J. Schaaf, David J. Zold
  • Patent number: 6028060
    Abstract: A method of treating a chronic inflammatory disease such as rheumatoid arthritis or psoriasis includes treating a patient with a toxin derived from Group B .beta.-hemolytic Streptococcus bacteria. The purified GBS toxin, or CM101, may be administered intravenously to the patient in repeated doses.
    Type: Grant
    Filed: January 29, 1997
    Date of Patent: February 22, 2000
    Assignee: Vanderbilt University
    Inventors: Carl G. Hellerqvist, Barbara D. Wamil
  • Patent number: 6028111
    Abstract: The use of benzamide and nicotinamide analogs, in particular N-substituted benzamides and nicotinamides, other than benzamides with N-pyridinyl substitutions, as anti-inflammatory agents.
    Type: Grant
    Filed: February 27, 1997
    Date of Patent: February 22, 2000
    Assignee: OXiGENE, Inc.
    Inventors: Ronald W. Pero, David Chaplin
  • Patent number: 6025334
    Abstract: The present invention relates to cartilage extracts and to a method of producing the same. Shark cartilage extracts having anti-angiogenic, direct anti-tumor proliferating, anti-inflammatory and anti-collagenolytic activities have been obtained by an improved process. The process comprises the steps of obtaining a homogenate of cartilage in an aqueous solution, this homogenate being centrifuged and further fractionated to obtain a total extract having molecules of a molecular weight comprised between 0 to 500 KDa. The composition of the liquid extract has then been investigated by different ways. Further fractionation of this extract led to the preliminary characterization of some of its active components. Due to the multiplicity of biological activities of the total liquid extract, it can be used for treating numerous diseases or conditions such as those having components selected from the group consisting of tumor proliferation, angiogenesis, inflammation and collagenolysis.
    Type: Grant
    Filed: October 30, 1995
    Date of Patent: February 15, 2000
    Assignee: Les Laboratoires Aeterna Inc.
    Inventors: Eric Dupont, Paul Brazeau, Christina Juneau, Daniel H. Maes, Kenneth Marenus
  • Patent number: 6020323
    Abstract: Substances comprising disaccharides and substances comprising carboxylated and/or sulfated oligosaccharides in substantially purified form, and methods of using same, are disclosed for the regulation of cytokine activity in a host. For instance, the secretion of active Tumor Necrosis Factor Alpha (TNF-.alpha.) can be either inhibited or augmented selectively by administration to the host of an effective amount of a substance of the invention. Thus, the present invention also relates to pharmaceutical compositions and their use for the prevention and/or treatment of pathological processes involving the induction of active cytokine secretion, such as TNF-.alpha.. The invention also relates to the initiation of a desirable immune system-related response by the host to the presence of activators, including pathogens. The substances and pharmaceutical compositions of the present invention may be administered daily, at very low effective doses, typically below 0.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 1, 2000
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Irun R. Cohen, Ofer Lider, Liora Cahalon, Oded Shoseyov, Raanan Margalit
  • Patent number: 6017551
    Abstract: A salve or skin care product for treating discomfort due to burned, inflamed or irritated skin includes a mixture of naturally occurring neutral organic glyceryl esters of fatty acids, such as lard, and small particles of the bark of an Alder tree. The small particles are obtained by pulverized, milling or the like.
    Type: Grant
    Filed: December 11, 1998
    Date of Patent: January 25, 2000
    Inventor: George E. Riley
  • Patent number: 6013674
    Abstract: This invention provides novel indenone derivatives, their pharmaceutical formulations and their use for the inhibition of leukocyte adherence to cells.
    Type: Grant
    Filed: May 1, 1998
    Date of Patent: January 11, 2000
    Assignee: Eli Lilly and Company
    Inventors: John Michael Morin, Jr., Michael Dean Kinnick, Robert Theodore Vasileff, William Thomas Jackson
  • Patent number: 6004566
    Abstract: The present invention relates to a delivery system which includes a bioactive drug or cosmetic substance presented in the form of submicron oil spheres alone, or drugs or cosmetic substances in a combination with the oil spheres in an aqueous suspension or emulsion. Optionally, a skin penetration enhancer may be included in such formulations. Such preparations achieve improved bioavailability and exert larger pharmacological effects than an equivalent dose of the drug or cosmetic formulated in conventional creams, lotions or oleaginous bases.
    Type: Grant
    Filed: March 23, 1993
    Date of Patent: December 21, 1999
    Assignee: Pharmos Corp.
    Inventors: Doron Friedman, Joseph Schwartz, Haim Aviv
  • Patent number: 5998476
    Abstract: The invention provides polyunsaturated fatty acid compounds having antimalarial and/or neutrophil stimulatory activity, or anti-inflammatory activity. The polyunsaturated fatty acids contain a 16-26 carbon chain, 3-6 double bonds and are covalently coupled at the carboxylic acid group to an amino acid. It is preferred that the fatty acid contains 18-22 carbons and that the amino acid is glycine or aspartic acid. Preferred compounds are .gamma.-linolenic acid-glycine, .alpha.-linolenic acid-glycine, arachidonic acid-aspartic acid, eicosapentaenoic acid-aspartic acid and docosahexaenoic acid-aspartic acid.
    Type: Grant
    Filed: July 21, 1997
    Date of Patent: December 7, 1999
    Assignee: Peptide Technology Limited
    Inventors: Merilyn Joy Sleigh, Fred Widmer, Paul Adam Schober, Antonio Ferrante, Alfred Poulos, Deborah Ann Rathjen
  • Patent number: 5997876
    Abstract: This invention refers to the sphere of medicine, in particular to pharmaceutics and concerns the preparations for burn treatment. The technical result of the present invention is in widening the assortment of medicinal preparations for treatment of bums and wounds, in increasing treatment effect. The ointment contains the components in the following relation of mass parts:______________________________________ celandine Chelidonium majus 15-25 g plantain Plantago major 15-25 g matricary Matricaria chamomilla 15-25 g yarrow Achillea millefolium 15-25 g calendula Calendula officinalis 15-25 g St.
    Type: Grant
    Filed: November 10, 1998
    Date of Patent: December 7, 1999
    Inventors: Nino Shikhashvili, Zurab Darsavelidze
  • Patent number: 5994341
    Abstract: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 30, 1999
    Assignee: Angiogenesis Technologies, Inc.
    Inventors: William L. Hunter, Lindsay S. Machan, A. Larry Arsenault
  • Patent number: 5993830
    Abstract: The present invention relates to a skin preparation comprising lipophilic and hydrophilic components, which is intended for application on skin. The skin preparation according to the present invention is characterized in that it exists as a two-phase system and it is capable of creating a semi-permeable membrane in the skin. The invention also relates to a process for the manufacture of the skin preparation as defined above, which is characterized in that the lipophilic components are dissolved in water in a separate container to be combined with hydrophilic components, which have been blended and brought to react in another vessel. Finally, the present invention also relates to different uses of the skin preparation as defined above.
    Type: Grant
    Filed: January 16, 1998
    Date of Patent: November 30, 1999
    Assignee: Ponsus AB
    Inventor: Goran Freij
  • Patent number: 5989595
    Abstract: A composition of matter and the method of making that provides a low pH acidic composition that is useful for destroying microorganisms that are undesirable and useful for destroying or reducing melanoma on human skin. The composition and method include sulfuric acid combined with distilled water and ammonium sulfate under at least 15 psi pressure in a pressurized container, all of which is heated to around 1200.degree. F. for at least 3 hours. The final cooled mixture is stabilized with 10 percent of the original mixture. The resultant composition is useful for preserving food, such as fresh fish, and for skin treatment of melanoma.
    Type: Grant
    Filed: March 8, 1996
    Date of Patent: November 23, 1999
    Inventor: Barry W. Cummins
  • Patent number: 5989559
    Abstract: An extract composition derived from the peel of a banana and the method for producing the extract composition. An aqueous solvent is combined with the peel of a banana. If the banana is unripe, a base is also added. The mixture is homogenized and allowed to react at least until a black supernatant appears. The entire slurry is filtered. The resulting extract is used alone or combined with a cream or ointment. Medicinal benefits of the extract include relief from pain, swelling, itching, bruising, wrinkles, and sunburn.
    Type: Grant
    Filed: January 29, 1998
    Date of Patent: November 23, 1999
    Assignee: Delft Pharma International
    Inventor: Bobby Gene Edwards
  • Patent number: 5985261
    Abstract: A method to increase cellular MnSOD production in an animal to treat oxidative damage by administering a protein having a thioredoxin active-site in reduced state. A composition and a method to protect an animal from lung disease are provided.
    Type: Grant
    Filed: June 27, 1997
    Date of Patent: November 16, 1999
    Assignee: National Jewish Medical and Research Center
    Inventors: Carl W. White, Kumuda C. Das
  • Patent number: 5985839
    Abstract: The present invention relates to shark cartilage extracts and to a method of producing the same, these extracts having anti-angiogenic properties (reduction of the area of blood vessels observed in vivo on experimentally induced tumors), tumor regressive activity in vivo as well as demonstrating a direct inhibitory effect on tumor cell lines. This process does not involve any denaturing solvent or product and does not involve the use of any enzymes. It consists of obtaining a blend of whole cartilage in an aqueous solution of neutral pH, preferably pure water, this blend being centrifuged and the pellet and supernatant kept for further processing. The pellet is lyophilized and tested for anti-tumor and anti-angiogenic activities in vivo and in vitro, with or without supernatant. The supernatant has been shown to have anti-angiogenic and tumor regressive activities in vivo. The composition of the supernatant has then been investigated by different ways.
    Type: Grant
    Filed: October 8, 1996
    Date of Patent: November 16, 1999
    Assignee: Les Laboratories Aeterna Inc.
    Inventors: Eric Dupont, Paul Brazeau, Christian Juneau
  • Patent number: 5985918
    Abstract: The present invention relates to the use of organic salts of zinc in topical formulations. Such organic salts tend to be less water soluble and therefore less likely to result in systemic toxicity, even with chronic use. In preferred embodiments, the composition of the invention comprise zinc salicylate, which provides the antiinflammatory effect of salicylate, but wherein the zinc moiety counteracts toxic effects associated with salicylate.
    Type: Grant
    Filed: December 4, 1996
    Date of Patent: November 16, 1999
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Shanta Modak, Lester Sampath, Lauserpina Caraos
  • Patent number: 5981497
    Abstract: This invention relates to a new use of a sophorolipidic compound, of pharmaceutically acceptable salts of the acidic form of the sophorolipid, and of the ester of the deacetylated sophorolipidic acid form as therapeutically active substances in a method for therapeutic treatment of the human or animal body, and more particularly as an activator of macrophages, as a fibrinolytic agent, as a healing agent, as a desquamating agent, and as a depigmenting agent.
    Type: Grant
    Filed: December 29, 1997
    Date of Patent: November 9, 1999
    Assignee: Institut Francais du Petrole
    Inventor: Martine Maingault
  • Patent number: 5972344
    Abstract: An extract composition derived from the peel of a banana and the method for producing the extract composition. An aqueous solvent is combined with the peel of a banana. If the banana is unripe, a base is also added. The mixture is homogenized and allowed to react at least until a black supernatant appears. The entire slurry is filtered. The resulting extract is used alone or combined with a cream or ointment. Medicinal benefits of the extract include relief from pain, swelling, itching, bruising, wrinkles, and sunburn.
    Type: Grant
    Filed: January 14, 1999
    Date of Patent: October 26, 1999
    Inventor: Bobby Gene Edwards
  • Patent number: 5973010
    Abstract: A composition and method for treating epidermal wounds utilizes an aqueous solution of sodium sulphate, sodium carbonate, sodium bicarbonate, sodium chloride and ichthammol.
    Type: Grant
    Filed: May 15, 1998
    Date of Patent: October 26, 1999
    Inventor: Robert L. Crawford
  • Patent number: 5968519
    Abstract: Method for the treatment of inflammation and pain associated with inflammatory dermatoses, gingivitis and acute injury with a composition of finely divided powder of safflower seed or its extract contained in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 15, 1998
    Date of Patent: October 19, 1999
    Inventors: Parvin Youssefyeh, Ronit Y. Arginteanu
  • Patent number: 5958887
    Abstract: The present invention relates to the use of hymenoptera venom or proteinaceous or polypeptide components contained therein in the manufacture of a medicament for treating DNA virus infections, and to a method for treatment of mammalian DNA virus infections which uses hymenoptera venom or proteinaceous or polypeptide components contained therein.
    Type: Grant
    Filed: June 22, 1998
    Date of Patent: September 28, 1999
    Inventors: Michael Hansen, Ole Gyring Nieben
  • Patent number: 5958462
    Abstract: Therapeutic bath salts for the relaxation of muscles, elimination or reduction of muscle spasms, and for the overall enhancement of a person's mood. The bath salts of the present invention are used as aromatherapy that has both the convenience of a bath and the internal mechanisms of ingested medication. The formula for the composition of the present invention includes a selected amount of magnesium sulfate trihydrate (a hydrated version of epsom salts), lithium chloride, copper gluconate, and essential oils. The oils include rosewood oil, ylang ylang oil, lavender oil and patchouli oil. The oils are provided as scents for use in the prescribed aromatherapy. The user mixes a preselected amount of the crystallized salt or liquid form of the present invention with the bath water. A period of time is allowed to elapse before the user departs the bath. By resting in the tub, the user accrues the combined benefits of external therapy and internal therapy.
    Type: Grant
    Filed: May 23, 1997
    Date of Patent: September 28, 1999
    Inventor: Linsey McLean
  • Patent number: 5958437
    Abstract: The invention is a dermatological healing kit having a pigment stabilizer component, and an antiinflammatory emollient component, and these components each by themselves, wherein the pigment stabilizer contains a mixture of glycerine, butylene glycol, bearberry extract, and mitracarpe extract; magnesium ascorbyl phosphate; and tricholoma matsutake singer; and the antiinflammatory emollient component contains xanthoxylum bungeanum planch; decarboxy camosine chlorhydrate; polygonum multiforum thumb; rubus thunbergii hance.cum spp.; and an aqueous mixture of siegerbecka orientals extract.
    Type: Grant
    Filed: February 12, 1998
    Date of Patent: September 28, 1999
    Assignee: Geneda Corporation
    Inventor: Chanda Zaveri
  • Patent number: 5958401
    Abstract: Provided by the present invention are methods of treating psoriasis using IL-11.
    Type: Grant
    Filed: December 10, 1997
    Date of Patent: September 28, 1999
    Assignee: Genetics Institute, Inc.
    Inventors: James Keith, Paul Schendel
  • Patent number: 5951989
    Abstract: A method for the treatment of dry skin by applying an effective amount of thyroid hormone in a pharmaceutically acceptable carrier to the skin.
    Type: Grant
    Filed: April 7, 1997
    Date of Patent: September 14, 1999
    Inventor: Warren R. Heymann
  • Patent number: 5948821
    Abstract: The progression of infection and other pathologies produced by a viral infection may be inhibited by administering an effective dosage of Ajoene. Additionally, Ajoene has anti-tumor, anti-shock, and antiinflammation effects. In general, Ajoene may be used to treat any integrin-mediated disease or condition.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: September 7, 1999
    Assignee: John B. Davidson
    Inventors: Alexander V. Tatarintsev, Ali S. Turgiev, John B. Davidson
  • Patent number: 5935585
    Abstract: Novel pharmaceutically/cosmetically-active biaromatic amido compounds have the structural formula (I): ##STR1## in which Ar is a radical selected from among those of the following formulae (a)-(e): ##STR2## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.
    Type: Grant
    Filed: February 23, 1996
    Date of Patent: August 10, 1999
    Assignee: Centre International de Recherches Dermatologiques Galderma
    Inventors: Jean-Michel Bernardon, Laurence Vigne
  • Patent number: 5932230
    Abstract: An analgesic cosmetic formulation in the form of an ointment, salve or cream which is applied to the skin, including the hands and feet for the treatment of such conditions as redness, swelling, itching and soreness of the skin. The cosmetic formulation contains ingredients including oranges, avocado, watermelon, banana, lemon, palm oil, coconut oil, petroleum jelly, beeswax, aloe vera, vitamin E, aspirin, ammonium sulfate, sodium bisulfate and quine sulfate.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: August 3, 1999
    Inventor: Frenchell DeGrate